Posted by Michael Wonder on 29 May 2026
AbbVie’s Elahere clears first reimbursement hurdle for platinum-resistant ovarian cancer in Korea
28 May 2026 - AbbVie’s ovarian cancer drug Elahere has cleared its first hurdle toward reimbursement coverage in Korea, potentially opening a new treatment option for patients with platinum-resistant ovarian cancer who have faced limited therapeutic choices.
On Wednesday, HIRA convened the fifth Cancer Disease Review Committee meeting to evaluate applications for oncology drug reimbursement and expanded reimbursement coverage.
